<DOC>
	<DOCNO>NCT00074438</DOCNO>
	<brief_summary>This study ass efficacy safety different treatment regimen rituximab ( MabThera®/Rituxan® ) , corticosteroid , placebo , combine methotrexate ( MTX ) , patient active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Rituximab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Eligibility criterion include , limited following : Are age 18 80 year . Have diagnose rheumatoid arthritis least 6 month . Have fail treatment ( lack efficacy ) least 1 5 diseasemodifying antirheumatic drug biologics ( methotrexate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>RA</keyword>
</DOC>